程序性死亡受体1抑制剂联合安罗替尼治疗广泛期小细胞肺癌疗效和安全性

Efficacy and safety of programmed death 1 inhibitor combined with anlotinib in the treatment of extensive-stage advanced small cell lung cancer

目的分析程序性死亡受体1(PD-1)抑制剂联合安罗替尼治疗广泛期小细胞肺癌的疗效和安全性。方法收集2018年1月至2020年6月郑州大学第一附属医院经标准化疗失败的应用PD-1抑制剂联合安罗替尼治疗的25例广泛期小细胞肺癌患者临床资料。结果所有患者均接受3~14个周期的治疗,有效率为12.00%,疾病控制率为56.00%,1例因疾病进展死亡,中位疾病无进展生存时间为5.6个月。主要不良反应为Ⅰ、Ⅱ度血液学毒性和消化道反应。结论PD-1抑制剂联合安罗替尼治疗小细胞肺癌显示出较好的疗效,耐受性好,可作为广泛期小细胞肺癌标准化疗失败后的选择。

Objective To analyze the efficacy and safety of programmed death 1(PD-1)inhibitor combined with anlotinib in the treatment of extensive-stage small cell lung cancer.Methods From January 2018 to June 2020,the data of 25 patients with extensive-stage small cell lung cancer who had failed standard chemotherapy and were treated with programmed death-1(PD-1)inhibitor combined with anlotinib were collected from the First Affiliated Hospital of Zhengzhou University.Results All the patients received 3 to 14 cycles of treatment,the response rate was 12.00%,the disease control rate was 56.00%,1 patient died due to disease progression,the median progression-free survival was 5.8 months.Adverse events were mainly gradeⅠandⅡhematological toxicities and digestive tract reactions.Conclusion PD-1 inhibitor combined with anlotinib showed better efficacy and good tolerability in the treatment of small cell lung cancer.It can be used as a choice after the failure of standard treatment of extensive-stage small cell lung cancer.